Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 701–800 of 1,000
Min, H.-K., Zhao, H., Bahcheli, A. T., Pan, P., Chan, J., Chen, J., Low, E., Zhou, Y., Wang, X., Bajic, S., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01487-5 · Cited by 12
Optimizing therapeutic outcomes with Mechanotherapy and Ultrasound Sonopermeation in solid tumors
Koutsi, M., Stylianopoulos, T., & Mpekris, F. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012676 · Cited by 13
“Nevertheless, it is important to note that the efficacy of mechanother-apeutics is somewhat limited, as they are only able to decompress a fraction of the compressed blood vessels within the tumor, rather than achieving comprehensive decompression of all vessels [23].”
Self-citationDeciphering the liver’s role in pancreatic cancer metastasis: pathways and therapeutic approaches
Inzunza, J., & del Valle, A. C. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01202-2 · Cited by 13
“According to emerging evidence, the thick collagen matrix is thought to provide resistance to anti-PDAC treatments 72,73 .”
Fu, Y., Li, M., Wu, S., Wang, J., & Wang, S. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08685-2 · Cited by 15
Li, Y., Tang, Y., Chen, S., Liu, Y., Wang, S., Tian, Y., Wang, C., Teng, Z., & Lu, G. (2019) · RSC Advances · doi:10.1039/c9ra02180a · Cited by 11
Li, J., Wu, X. F., Ni, X., Li, Y.-X., Xu, L., Hao, X., Zhao, W., Zhu, X., & Yin, X. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1213 · Cited by 13
Peveling‐Oberhag, J., Seiz, A., Döring, C., Hartmann, S., Köberle, V., Liese, J., Zeuzem, S., Hansmann, M., & Piiper, A. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.09.003 · Cited by 12
“Moreover, the TC may result in a reduced accessibility of solid tumors for systemic chemotherapies [45,46].”
BackgroundSousa-Junior, A. A., Yang, C.-T., Korangath, P. C., Ivkov, R., & Bakuzis, A. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415664 · Cited by 11
“applied this latter adaptation to successfully predict delivery efficiency of erythrocyte membrane-camouflaged magneto-fluorescent nanocarriers in two different mouse tumor models (Ehrlich and Sarcoma 180), before and after the TME was manipulated to enhance tumor uptake [15,16].”
MethodWu, Q., Xia, Y., Xiong, X., Duan, X., Pang, X., Zhang, F., Tang, S., Su, J., Wen, S., Mei, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1169608 · Cited by 14
New Roles for Vitamin D Superagonists: From COVID to Cancer
Easty, D. J., Farr, C. J., & Hennessy, B. T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.644298 · Cited by 13
Blanchard, R., & Adjei, I. M. (2023) · RSC Advances · doi:10.1039/d3ra01153d · Cited by 11
Harkos, C., & Stylianopoulos, T. (2024) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2024.111768 · Cited by 11
Self-citationThe multi-faceted roles of cancer-associated fibroblasts in pancreatic cancer
Kwon, J. Y., Vera, R. E., & Fernández-Zapico, M. E. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111584 · Cited by 11
Targeting stromal components in pancreatic ductal adenocarcinoma: a review
Shihadeh, H., Yousef, A. A., Al-leimon, A., Abu-Rumman, H., & Kreshan, L. (2025) · ecancermedicalscience · doi:10.3332/ecancer.2025.1996 · Cited by 13
Impact of the ECM on the Mechanical Memory of Cancer Cells
Mierke, C. T. (2025) · Cells · doi:10.3390/cells14211707 · Cited by 11
Zhai, X., Tang, S., Meng, F., Ma, J., Li, A., Zou, X., Zhou, B., Peng, F., & Bai, J. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213650 · Cited by 10
Liang, C., Zhang, G., Guo, L., Ding, X., Yang, H., Zhang, H., Zhang, Z., & Hou, L. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100888 · Cited by 15
“It has been reported that valsartan (Val) can inactivate CAFs [26] , reduce TGF-β secretion and downregulate collagen expression [27] .”
BackgroundFrom darkness to light: Targeting CAFs as a new potential strategy for cancer treatment
Tian, H., Wang, W., Liang, S., Ding, J., & Hua, D. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113482 · Cited by 11
Ou, G., & Weaver, V. M. (2015) · BioEssays · doi:10.1002/bies.201500090 · Cited by 11
Brücher, B. L. D. M., & Jamall, I. S. (2019) · 4open · doi:10.1051/fopen/2018996 · Cited by 10
Qian, X., Shen, T., Zhang, X., Wang, C., Cai, W., Cheng, R., & Jiang, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00516a · Cited by 10
Hepatocyte fate upon TGF-β challenge is determined by the matrix environment
Meyer, C., Liebe, R., Breitkopf‐Heinlein, K., Liu, Y., Müller, A., Rakoczy, P., Thomas, M., Weng, H., Bachmann, A., Ebert, M. P. A., et al. (2015) · Differentiation · doi:10.1016/j.diff.2015.04.001 · Cited by 10
“Our study offers further mechanistic explanation why loosening the collagen structure surrounding tumors may result in increased responsiveness to chemotherapy (Chauhan et al., 2013).”
BackgroundPancreatic cancer: a mechanobiology approach
Chronopoulos, A., Lieberthal, T. J., & Hernández, A. E. D. R. (2017) · Convergent Science Physical Oncology · doi:10.1088/2057-1739/aa5d1b · Cited by 10
Galiè, M., Boschi, F., Scambi, I., Merigo, F., Marzola, P., Altabella, L., Lavagnolo, U., Sbarbati, A., & Spinelli, A. E. (2017) · Theranostics · doi:10.7150/thno.21403 · Cited by 10
“CLI: Cerenkov Luminescence Imaging; IFP: Interstitial fluid pressure; CR: Cerenkov radiation; PBS: Phosphate-Buffered Saline; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling; DCE-MRI: Contrast-enhanced magnetic resonance imaging; FoV: field of view; ROIs: regions of interest.”
BackgroundInfluentialMeasuring Vascular Permeability in Mice
Jain, R. K., Munn, L. L., & Fukumura, D. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot074344 · Cited by 10
Self-citationDiao, B., Fan, Z., Zhou, B., & Zhan, H. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151012 · Cited by 9
Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors
Chaudhuri, T. R., Lin, Q., Stachowiak, E. K., Rosario, S. R., Spernyak, J. A., Ma, W. W., Stachowiak, M. K., Greene, M. K., Quinn, G. P., McDade, S. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0131 · Cited by 11
Mechano-assisted strategies to improve cancer chemotherapy
Zhu, S., Jin, G., He, X., Li, Y., Xu, F., & Guo, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123178 · Cited by 10
Leveraging Microneedles for Raised Scar Management
Jin, Z.-Y., Kim, Y., & Lim, J. Y. (2025) · Polymers · doi:10.3390/polym17010108 · Cited by 9
“Losartan, a potent angiotensin II receptor blocker, works by selectively blocking the AT1 receptor, thereby inhibiting the pro-fibrotic and pro-inflammatory actions of angiotensin II [104].”
Angiogenic Networks in Tumors—Insights via Mathematical Modeling
Dorraki, M., Fouladzadeh, A., Allison, A., Bonder, C. S., & Abbott, D. (2020) · IEEE Access · doi:10.1109/access.2020.2977062 · Cited by 10
“Experimental studies illustrate that the patients with low tumor perfusion show poorer response to chemotherapy and therefore shorter survival in comparison of patients with high perfusion [156]–[158].”
BackgroundMainetti, L. E., Rico, M. J., Kaufman, C. D., Grillo, M. C., Guercetti, J., Baglioni, M. V., Giúdice, A. D., Capitani, M. C., Fusini, M. E., Rozados, V. R., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27694 · Cited by 10
Transiently hypoxic tumour cell turnover and radiation sensitivity in human tumour xenografts
Wadsworth, B. J., Lee, C.-M., & Bennewith, K. L. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01691-5 · Cited by 9
Labenz, C., Prenosil, V., Koch, S., Huber, Y., Marquardt, J. U., Schattenberg, J. M., Galle, P. R., Weinmann, A., & Wörns, M. (2017) · Digestive Diseases · doi:10.1159/000477578 · Cited by 9
Guerrero‐López, P., Alamán‐Díez, P., Hernández-Hatibi, S., Balsas, P., & Garcia-Aznar, J. M. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115836 · Cited by 9
Asgharzadeh, F., Geraylow, K. R., Khazaei, M., Avan, A., Nassiri, M., Hassanian, S. M., & Ferns, G. A. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220517104411 · Cited by 8
Chattopadhyay, S., Liao, Y., Wang, X., & Nel, A. E. (2023) · Bioengineering · doi:10.3390/bioengineering10101205 · Cited by 10
“The CAF secretome further plays a role in the recruitment of tumor-associated macrophages (TAMs), which contributes to the development of an immunosuppressive TME [26–28].”
BackgroundEngineering Nanosensitizer to Remodel the TME for Hypoimmunogenic “Cold”–“Hot” Tumor Transformations
Liu, Z., Wang, Z., Zhang, Z., Zhang, Z., Qi, X., Zhu, H., Zhang, K., Qu, T., Zhao, Y., Kang, Z., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c03816 · Cited by 10
Targets in the Tumour Matrisome to Promote Cancer Therapy Response
Jalil, S. M. A., Henry, J. C., & Cameron, A. J. M. (2024) · Cancers · doi:10.3390/cancers16101847 · Cited by 10
“The most abundant protein component of the TME, and indeed the human body, is type 1 collagen, and collagen-rich tumour fibrosis has long been considered as a barrier to therapy, particularly in fibrotic tumours such as PDAC [18,75,95,96].”
BackgroundImpact of angiotensin system inhibitors on esophageal cancer survival
Wang, X., Sweigert, P. J., Eguia, E., Varsanik, M. A., Renz, C. R., Terrasse, W., Gauthier, M. M., Aranha, G. V., Knab, L. M., & Abood, G. J. (2020) · Surgery Open Science · doi:10.1016/j.sopen.2020.08.001 · Cited by 8
“Specifically, ASI use has been proposed as an adjunct to standard adjuvant treatment algorithms in patients with advanced pancreatic cancer due to an association with improved OS and disease-free survival (DFS) [12].”
BackgroundInfluentialKumar, B. S. (2023) · Mass Spectrometry · doi:10.5702/massspectrometry.a0129 · Cited by 9
Implantable tissue isolation chambers for analyzing tumor dynamics in vivo
Gruionu, G., Bazou, D., Maimon, N., Lenco, M. O., Gruionu, L. G., Huang, P., & Munn, L. L. (2016) · Lab on a Chip · doi:10.1039/c6lc00237d · Cited by 8
Self-citationThe emergence of solid stress as a potent biomechanical marker of tumour progression
Vella, A., Eko, E. M., & Hernández, A. E. D. R. (2018) · Emerging Topics in Life Sciences · doi:10.1042/etls20180049 · Cited by 11
Sequential Drug Release to Modulate Collagen Synthesis and Promote Micelle Penetration in Tumors
Chen, Z., Liu, W., Wang, X., Liu, Y., & Li, X. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01600 · Cited by 8
Ding, H., Sun, J., Song, Y., Xin, W., Zhu, J., Zhong, L., Chen, Y., Zhang, Y., Tong, Y., & Fang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632352 · Cited by 8
“The incomplete intratumoral distribution of gemcitabine and fluorouracil, which induced the reverse impact of the antitumor effect, has been addressed in vivo (21, 45).”
BackgroundBai, S., Chen, L., Yan, Y., Li, R., Zhou, Y., Wang, X., Kang, H., Feng, Z., Li, G., Zhou, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.853352 · Cited by 8
“Studies found that losartan impairs collagen and hyaluronan deposition in various malignancies, reducing hypoxia status and improving tissue perfusion (43, 44).”
BackgroundNobis, M., McGhee, E. J., Herrmann, D., Magenau, A., Morton, J. P., Anderson, K. I., & Timpson, P. (2014) · Cell Adhesion & Migration · doi:10.4161/19336918.2014.970004 · Cited by 9
“This has recently been shown with angiotensin inhibition and the associated downstream decrease in expression of profibrotic signals such as transforming growth factor (TGF)-b1, connective tissue growth factor (CTGF) and endothelin (ET)-1.(32) Here, the authors show that stress exerted upon vessels by excessive deposi…”
BackgroundOh, T., Kim, M.-W., Kang, G.-S., Ye, S., Choi, C., Park, W., Hay, M. P., Hirata, H., & Ahn, G. (2025) · Cancer Research and Treatment · doi:10.4143/crt.2025.200 · Cited by 8
“Losartan, an angiotensin II receptor inhibitor, has been shown to decrease tumor hypoxia by alleviating the tumor interstitial pressure exerted by collagen I production from cancer-associated fibroblasts [90].”
Srinivasan, D., Gout, J., Kleger, A., & Roger, É. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115697 · Cited by 11
Costamagna, A., Noemi, G., & Martini, M. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1726581 · Cited by 7
Angeli, S., Neophytou, C., Charalambous, A., Voutouri, C., Themistokleous, P., Stylianopoulos, T., & Mpekris, F. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114546 · Cited by 9
Self-citationOvercoming biophysical barriers with innovative therapeutic delivery approaches
Pavuluri, S., & Sheth, R. A. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00529-3 · Cited by 8
Enjalbert, R., Krüger, T., & Bernabéu, M. O. (2024) · Communications Physics · doi:10.1038/s42005-023-01510-8 · Cited by 8
Molecular and supramolecular characterization of Ni(II)/losartan hydrophobic nanoprecipitate
Nascimento, L. O., Guimarães, P. P. G., Correa, J. L., Abrishamkar, A., Silva, J. G. D., Mangrich, A. S., França, A., & Denadai, Â. M. L. (2014) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2014.05.080 · Cited by 7
Histological tumor necrosis in pancreatic cancer after neoadjuvant therapy
Kudo, M., Ishii, G., Gotohda, N., Konishi, M., Takahashi, S., Kobayashi, S., Sugimoto, M., Martin, J. D., Cabral, H., & Kojima, M. (2022) · Oncology Reports · doi:10.3892/or.2022.8332 · Cited by 7
Self-citationde Scordilli, M., Michelotti, A., Zara, D., Palmero, L., Alberti, M., Noto, C., Totaro, F., Foltran, L., Guardascione, M., Iacono, D., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104013 · Cited by 7
Cancer-associated fibroblasts in neoadjuvant setting for solid cancers
Gu, Y., Chen, Q., Yin, H., Zeng, M., Gao, S., & Wang, X. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104226 · Cited by 8
Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update
Ilmer, M., Westphalen, C. B., Nieß, H., D’Haese, J. G., Angele, M. K., Werner, J. M., & Renz, B. W. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000372 · Cited by 8
Koutsi, M., Stylianopoulos, T., & Mpekris, F. (2025) · Frontiers in Drug Delivery · doi:10.3389/fddev.2025.1549098 · Cited by 8
Self-citationPapadopoulou, S., Michou, V., Tsiotsias, A., Tzitiridou‐Chatzopoulou, M., & Eskitzis, P. (2026) · Cancers · doi:10.3390/cancers18030404 · Cited by 8
“The high interstitial fluid pressure further exacerbates this issue [22,25–29,96 As a result, this barrier effect significantly reduces treatment efficacy, which can help explain the development of therapy resistance [22,26,96,100,121].”
Daniaty, T. O. W., Wardani, I. A. K., & Ariani, N. K. P. (2022) · International journal of health & medical sciences · doi:10.21744/ijhms.v5n4.1947 · Cited by 6
“It is said the patient often complains of itching in the wound and looks sad face (Battiston et al., 2002; Chauhan et al., 2013; Nisa, 2021).”
BackgroundSmart Cancer Nanomedicine for Synergetic Therapy
Kanungo, A., Mohanty, C., & Acharya, S. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673300897240602130258 · Cited by 6
Fortune, K., Ali, S., Masur, J., Viscuse, P. V., Devitt, M. E., Dreicer, R., & Skelton, W. P. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102256 · Cited by 6
Tumor Biomechanics-Inspired Future Medicine
Dong, Y., Lu, M., Yin, Y., Wang, C., & Dai, N. (2024) · Cancers · doi:10.3390/cancers16234107 · Cited by 7
“Losartan, an angiotensin receptor inhibitor, can reduce solid stress by relieving the compression of blood vessels by hyaluronic acid and collagen, enhancing the delivery of drugs and oxygen [77].”
Fu, Y., Tu, W., He, Y., Du, Q., Xue, W., Zhang, X., Xu, Z., Li, Z., Wang, L., & Gao, D. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.138244 · Cited by 6
Moriyama, S., Hieda, M., Kisanuki, M., Kawano, S., Yokoyama, T., Fukata, M., Kusaba, H., Maruyama, T., Baba, E., Akashi, K., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0628 · Cited by 6
Zhao, P., Peng, Y., Wang, Y., Hu, Y., Qin, J., Li, D., Yan, K., & Fan, Z. (2023) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2023.106709 · Cited by 9
“The solid stress accumulating in tumors due to the proliferation of cancer and stromal cells collapses tumor blood vessels, reducing vascular perfusion and thus the delivery efficiency of chemo-therapeutic drugs [1].”
BackgroundHuang, Z., Cong, Z., Luo, J., Qiu, B., Wang, K., Gao, C., Xu, Y., Yang, N., Zou, Z., Hu, L., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03709-x · Cited by 7
“In fact, some clinical trials has proven that CAF-targeting drugs such as the angiotensin inhibitor-losartan [78] and depleting hyaluronic acid-PEGylated recombinant human hyaluronidase (PEGPH20) [79] can enhance the drug anti-tumor effect of chemotherapy.”
Apte, M. V., Pirola, R. C., & Wilson, J. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800134-9.00016-6 · Cited by 7
Liu, Y., Jian, J., Zhang, Y., Wang, L., Liu, X., & Chen, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170893 · Cited by 10
“Frontiers in Oncology 16 CAF promoting chemoresistance in part through the secretion of ECM proteins (59, 60).”
BackgroundZhang, B., Wang, H., Jin, K., Jiang, T., Shen, S., Luo, Z., Tuo, Y., Jiang, X., Liu, X., Hu, Y., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.017 · Cited by 6
Bai, R.-L., Wang, N.-Y., Zhao, L., Zhang, Y., & Cui, J. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.08.012 · Cited by 6
Ren, T., Jia, H., Wu, Q., Zhang, Y., Ma, Q., Yao, D., Gao, X., Xie, D., Xu, Z., Zhang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.829059 · Cited by 7
“Compared with those who received CCBs, patients who received ACEIs or ARBs had a longer PFS and OS.”
BackgroundInfluentialXi, H., Zhao, M., & Shen, J. (2025) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2025.05.015 · Cited by 5
Lipid nanoparticle-assisted mRNA therapy for cancer treatment
Kim, H.-J., Le, N. D., Oh, H.-J., Kim, B., Yoo, E., Kim, J., & Yim, H. (2025) · Applied Physics Reviews · doi:10.1063/5.0247029 · Cited by 6
Lin, M., Kang, X., Liu, F., Nie, J., Zhang, J., Zhuang, J., Yu, B., & Xu, F. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202513208 · Cited by 6
Enjalbert, R., Köry, J., Krüger, T., & Bernabéu, M. O. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013801 · Cited by 7
“In addition, drugs inhibiting collagen synthesis can decompress vessels, improving perfusion, oxygenation and drug delivery [22,30].”
Wang, Z.-P., Li, A.-Q., Wusiman, D., Wu, R., Zhu, J.-M., Li, X.-R., Guo, Y.-N., Chaipanichkul, P., Okoli, U. A., Koh, S., et al. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100038 · Cited by 7
Kluz, N., Kraj, L., Chmiel, P., Przybyłkowski, A. M., Wyrwicz, L. S., Stec, R., & Szymański, Ł. (2024) · Cancers · doi:10.3390/cancers16233945 · Cited by 5
“Consequently, losartan reduces solid stress and enhances vascular perfusion, leading to decreased tumor hypoxia and improved distribution and efficacy of anticancer drugs and nanotherapeutics [88].”
Valenti, G., Laise, P., Wu, F., Takahashi, R., Ruan, T., Vasciaveo, A., Jiang, Z., Kobayashi, H., Sunagawa, M., Middelhoff, M. A., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115734 · Cited by 6
Leveraging selection for function in tumor evolution: System-level cancer therapies
Thomas, F., Capp, J., Dujon, A. M., Marusyk, A., Asselin, K., Campone, M., Pujol, P., Alix‐Panabières, C., Roche, B., Újvári, B., et al. (2025) · Evolution Medicine and Public Health · doi:10.1093/emph/eoaf022 · Cited by 7
“Additionally, Losartan, an angiotensin II receptor blocker, has been found to modify the tumor microenvironment by reducing the density of CAFs and normalizing the extracellular matrix, enhancing the delivery of chemotherapeutic agents [33, 34].”
Turlej, E., Domaradzka, A., Koksharov, R., & Gizak, A. (2026) · Cancers · doi:10.3390/cancers18030344 · Cited by 6
The effect of mechanical force in genitourinary malignancies
Huang, K., Liu, J., Chen, Q., Feng, D., Wu, H., Al-Danakh, A., Jian, Y., Xu, Z., Wang, S., & Yang, D. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2000864 · Cited by 5
“Similarly, Losartan, an angiotensin II receptor antagonist(ARB), is used to decrease the collagen and hyaluronic acid levels of mice with breast and pancreatic cancers in order to increase perfusion and medication delivery [90,91].”
MethodBarsoumian, H. B., Sheth, R. A., Ramapriyan, R., Hsu, E. Y., Gagea, M., Crowley, K., Sezen, D., Williams, M. L., & Welsh, J. W. (2022) · Advances in Radiation Oncology · doi:10.1016/j.adro.2022.101137 · Cited by 5
“This difference could be due to a more resilient inhibitory stroma associated with the 344SQ-R model, leading to reduced cluster of differentiation 4 and 8 tumor infiltrating lymphocytes.(32) Low-dose XRT once again created an early window of decreased intratumoral pressure 1, 3, and 5 days after the last fraction of…”
BackgroundHuman intravital microscopy in the study of sarcomas: an early trial of feasibility
Gabriel, E. M., Sukniam, K., Popp, K., & Bagaria, S. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1151255 · Cited by 5
Haze, H., Sier, C. F. M., Vahrmeijer, A. L., & Vuijk, F. A. (2024) · Surgeries · doi:10.3390/surgeries5010007 · Cited by 5
“Losartan treatment in tumor tissue in animal models reduced IFP intratumorally and increased vascular perfusion, which was facilitated by a reduction in collagen and hyaluronan production [4].”
BackgroundExtracellular Matrix Degrading Enzymes for Nanocarrier-Based Anticancer Therapy
Scodeller, P. (2016) · Fundamental biomedical technologies · doi:10.1007/978-3-319-43525-1_3 · Cited by 5
Normalizing the Tumor Microenvironment for Radiosensitization
Martin, J. D., & Jain, R. K. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_12 · Cited by 5
Self-citationLi, S., Yu, C., Cheng, Y., Du, F., & Wen, G. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11832 · Cited by 5
“RAS can also promote tumor growth indirectly, for instance, by regulating cancer‐asso‐ ciated fibroblasts (38) and promoting VEGF‐mediated angiogenesis (39,40) in solid tumors.”
Tsang, E. S., & Tempero, M. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.22 · Cited by 5
Yoshida, G. J., Azuma, A., Miura, Y., & Orimo, A. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamb.1.2020.2 · Cited by 5
Liu, H., Nassour, I., Lebowitz, S., D’Alesio, M., Hampton, E. D., DeSilva, A., Hammad, A. Y., AlMasri, S. S., Khachfe, H. H., Singhi, A. D., et al. (2022) · HPB · doi:10.1016/j.hpb.2022.12.002 · Cited by 5
Self-citationSustainable biomedical microfibers from natural products
Guo, J., Cao, X., Luo, Z., Zhu, Y., Zhao, Y., & Gu, X. (2024) · Aggregate · doi:10.1002/agt2.549 · Cited by 5
Kuznetsov, M. B. (2021) · Mathematics · doi:10.3390/math9182213 · Cited by 5
Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research
Gorodetska, I., Samusieva, A. A., Lahuta, T., Ponomarova, O. V., Socha, O., & Kozeretska, I. A. (2025) · The Breast Journal · doi:10.1155/tbj/9952727 · Cited by 4
“Losartan has been shown to reduce solid stress in tumors, resulting in increased vascular perfusion and improved drug and oxygen delivery to tumors in breast and pancreatic cancer models [222].”
Zhang, H., Wang, Q., Li, J., Zhou, J., & Chen, Q. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115314 · Cited by 5
Charalambous, A., Mpekris, F., Voutouri, C., Neophytou, C., Djamus, J., Gupta, A., Gabizón, A., & Stylianopoulos, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114541 · Cited by 5
Self-citationAntibody–drug conjugates in gastric cancer: clinical advances and resistance mechanisms
Li, W., Cheng, M., Han, H., Xu, M., Luo, Y., Bi, F., & Liu, M. (2026) · Gastric Cancer · doi:10.1007/s10120-025-01703-w · Cited by 5
“This fibrotic stromal network can physically impede the penetration of large molecules like antibodies/ ADCs into the tumor tissue [103, 104 ].”
Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy
Jones, A. P., Zhao, Y., Rueda, B. V., Yeku, O., & Xu, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020939 · Cited by 4
“This reduction in solid stress and vascular compression correlated with improved vascular perfusion, resulting in decreased tumor hypoxia and improved delivery and efficacy of both small-molecule drugs and nanomedicine [19,20].”
Kong, X., Cheng, R., Zhang, W., Lu, Y., Kan, Y., Fang, Y., Gao, J., Wang, J., & Hwang, K. C. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101392 · Cited by 4
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.